FDA's Risk Communication Strategic Plan, At A Glance
You may also be interested in...
FDA Rule-Making Could Get Makeover Under Obama Administration
After GAO finds FDA one of the slower agencies in rulemaking, Rep. Towns asks for timeliness and transparency in White House input on federal regulations.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials